Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 7,826,789	$ 8,434,554
Short-term investments	20,815,405	35,837,309
Accounts receivable	98,035	81,456
Grant receivable	1,524,522	1,524,522
Income tax refund receivable	600,877	600,877
Prepaid expenses and other current assets	3,492,621	3,575,541
Total Current Assets	34,358,249	50,054,259
Property and Equipment, net	19,430,708	20,480,375
Intangible assets, net	8,305,625	8,669,375
Goodwill	3,301,959	3,301,959
Operating lease right-of-use asset	5,729,722	6,005,147
Finance lease right-of-use asset	14,554,625	15,329,075
Other assets	5,557,073	260,011
Deposits	279,990	296,711
Total Assets	91,517,951	104,396,912
Current Liabilities
Accounts payable	3,050,829	4,424,053
Deferred revenue, current portion	2,039,486	1,585,808
Operating lease liability, current portion	406,694	490,378
Finance lease liability, current portion	224,983	301,048
Accrued expenses and other liabilities	5,723,083	4,301,922
Contingent consideration, current portion	6,034,114	6,934,114
Total Current Liabilities	17,479,189	18,037,323
Long Term Liabilities
Deferred revenue, net of current portion	32,500	32,500
Operating lease liability, net of current portion	2,996,808	3,079,887
Financing lease liability, net of current portion	5,470,242	5,520,034
Contingent consideration, net of current portion	5,200,000	5,290,500
Total Liabilities	31,178,739	31,960,244
Commitments and Contingencies (Note 13 and Note 14)
Stockholders' Equity
Common stock, $0.0002 par value; 250,000,000 shares authorized, 26,049,209 and 25,661,488 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	5,210	5,126
Additional paid-in capital	283,785,089	283,019,456
Accumulated deficit	(221,938,306)	(209,153,659)
Accumulated other comprehensive income (loss)	83,887	51,924
Total Stockholders' Equity - NightHawk Biosciences, Inc.	61,935,880	73,922,847
Non-Controlling Interest	(1,596,668)	(1,486,179)
Total Stockholders' Equity	60,339,212	72,436,668
Total Liabilities and Stockholders' Equity	$ 91,517,951	$ 104,396,912